Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNMD CONMED	$54.33 +0.2%	$55.54	$46.00 ▼ $78.19	$1.68B	1.2	446,752 shs	250,665 shs
GKOS Glaukos	$103.50 -0.1%	$95.71	$77.10 ▼ $163.71	$5.91B	0.82	739,359 shs	289,937 shs
IRTC iRhythm Technologies	$142.37 -0.3%	$139.98	$55.92 ▼ $157.13	$4.54B	1.41	482,173 shs	206,877 shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.43 million shs	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNMD CONMED	+0.20%	+3.76%	-4.46%	-3.38%	-19.48%
GKOS Glaukos	-0.17%	+2.25%	+9.45%	+23.77%	-13.12%
IRTC iRhythm Technologies	-0.29%	-6.76%	-1.80%	+41.88%	+47.13%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+59.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNMD CONMED	4.725 of 5 stars	2.1	3.0	2.5	4.3	3.3	0.8	3.1
GKOS Glaukos	4.4561 of 5 stars	4.4	1.0	0.0	4.4	2.7	1.7	0.6
IRTC iRhythm Technologies	1.2305 of 5 stars	2.5	1.0	0.0	0.0	2.6	0.8	0.6
NARI Inari Medical	0.5418 of 5 stars	1.1	0.0	0.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNMD CONMED	2.20	Hold	$62.20	14.49% Upside
GKOS Glaukos	2.75	Moderate Buy	$134.67	30.11% Upside
IRTC iRhythm Technologies	2.90	Moderate Buy	$138.60	-2.64% Downside
NARI Inari Medical	2.14	Hold	$69.22	-13.44% Downside

Current Analyst Ratings Breakdown

Latest CNMD, GKOS, IRTC, and NARI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	CNMD CONMED	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$61.00
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/6/2025	GKOS Glaukos	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$110.00 ➝ $72.00
5/2/2025	GKOS Glaukos	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
5/2/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$152.00 ➝ $139.00
5/2/2025	IRTC iRhythm Technologies	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$133.00 ➝ $150.00
5/2/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$104.00 ➝ $130.00
5/2/2025	IRTC iRhythm Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $151.00
5/1/2025	CNMD CONMED	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$70.00 ➝ $58.00
5/1/2025	CNMD CONMED	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $57.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNMD CONMED	$1.31B	1.29	$6.73 per share	8.07	$31.16 per share	1.74
GKOS Glaukos	$383.48M	15.42	N/A	N/A	$13.91 per share	7.44
IRTC iRhythm Technologies	$591.84M	7.68	N/A	N/A	$2.90 per share	49.09
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNMD CONMED	$132.42M	$3.80	14.30	10.72	1.39	9.02%	14.36%	5.86%	7/30/2025 (Estimated)
GKOS Glaukos	-$146.37M	-$2.37	N/A	N/A	N/A	-31.40%	-10.66%	-8.06%	7/30/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/30/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A

Latest CNMD, GKOS, IRTC, and NARI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	CNMD CONMED	$1.13	N/A	N/A	N/A	$338.42 million	N/A
7/30/2025	Q2 2025	GKOS Glaukos	-$0.26	N/A	N/A	N/A	$115.49 million	N/A
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/30/2025	Q1 2025	CNMD CONMED	$0.81	$0.95	+$0.14	$0.19	$313.38 million	$321.26 million
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNMD CONMED	$0.80	1.47%	N/A	21.05%	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A

Latest CNMD, GKOS, IRTC, and NARI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/21/2025	CNMD CONMED	quarterly	$0.20	1.34%	6/13/2025	6/13/2025	7/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNMD CONMED	0.91	2.26	1.00
GKOS Glaukos	0.09	6.49	5.62
IRTC iRhythm Technologies	7.47	5.71	5.58
NARI Inari Medical	N/A	1.77	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNMD CONMED	N/A
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
NARI Inari Medical	90.98%

Insider Ownership

Company	Insider Ownership
CNMD CONMED	3.10%
GKOS Glaukos	5.80%
IRTC iRhythm Technologies	1.10%
NARI Inari Medical	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNMD CONMED	4,100	30.94 million	29.98 million	Optionable
GKOS Glaukos	780	57.14 million	53.83 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.57 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable

CNMD, GKOS, IRTC, and NARI Headlines

Recent News About These Companies

FDA grants 510(k) clearance to Stryker’s total ankle system

June 26, 2025 | medicaldevice-network.comM

Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors

June 18, 2025 | finance.yahoo.com

American Century Small Cap Growth Fund Q1 2025 Commentary

June 11, 2025 | seekingalpha.com

Thrombectomy system removes clots, improves quality of life for patients with PE

May 20, 2025 | healio.comH

The top nitinol cardiac medtech news of 2025 (so far)

May 13, 2025 | medicaldesignandoutsourcing.comM

Stryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPS

May 2, 2025 | msn.com

Expert Testimony Supporting POPR Can Be An Effective Strategy

April 21, 2025 | jdsupra.com

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

April 8, 2025 | finance.yahoo.com

8 spine, orthopedic acquisitions in Q1

March 27, 2025 | beckersspine.comB

Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter

March 26, 2025 | finance.yahoo.com

How Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?

March 25, 2025 | kalkinemedia.comK

If You Could Only Hold 3 Investments for Life, Consider These (NARI)

...

March 10, 2025 | marketbeat.com

Stryker’s Inari Medical Launches Artix Thrombectomy System

March 7, 2025 | evtoday.comE

Stryker’s Inari Medical launches Artex thrombectomy system

March 7, 2025 | massdevice.com

Inari Medical introduces thrombectomy system for arterial thrombus cases

March 7, 2025 | msn.com

Inari Medical acquisition could provide Stryker with foothold in peripheral vascular market

February 28, 2025 | expresshealthcare.inE

Wearable defibrillator maker Kestra Medical plots $150M IPO

February 26, 2025 | fiercebiotech.comF

Stryker grows cardiovascular division with Inari Medical acquisition

February 24, 2025 | medicaldevice-network.comM

Stryker Completes Acquisition of Inari

February 20, 2025 | evtoday.comE

Stryker concludes Inari Medical acquisition for $4.9bn

February 20, 2025 | finance.yahoo.com

Stryker completes Inari Medical acquisition

February 20, 2025 | beckersspine.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD, GKOS, IRTC, and NARI Company Descriptions

CONMED NYSE:CNMD

$54.33 +0.11 (+0.20%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$54.29 -0.04 (-0.07%)

As of 07/3/2025 04:20 PM Eastern

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Glaukos NYSE:GKOS

$103.50 -0.13 (-0.13%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$103.42 -0.08 (-0.07%)

As of 07/3/2025 04:20 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$142.36 -0.42 (-0.29%)

Closing price 07/3/2025 03:37 PM Eastern

Extended Trading

$142.36 0.00 (0.00%)

As of 07/3/2025 04:08 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time